March 2020

RHEUMATOLOGY

BALANCING HYDROXYCHLOROQUINE USE FOR COVID-19 AND LUPUS

Featuring: Rosalind Ramsey-Goldman, MD

Episode Summary

Recent promotion by several countries, including the United States, of hydroxychloroquine as an effective treatment for COVID-19 has left patients with systemic lupus erythematosus (lupus) facing a severe shortage of the medication on which they rely. How should rheumatologists balance the supply of hydroxychloroquine for testing and potential use in COVID-19 with its critical use in the treatment of lupus? How should they allocate the drug to their patients?

In this episode of the Better Edge ​podcast, Rosalind Ramsey-Goldman, MD, discusses key considerations for rheumatologists in the context of the COVID-19 pandemic, including the risks for patients with rheumatic conditions such as lupus, and how Northwestern Medicine Rheumatology is evolving care.  
Rosalind Ramsey-Goldman, MD, Solovy/ Arthritis Research Society Research Professor and professor of medicine in the Division of Rheumatology at Northwestern Medicine.

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like